300 ‘Junk Patents’ Targeted by FTC With Warning Letters, Including Ozempic
On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for improperly listed patents, and notified the FDA that it disputes the accuracy or relevance of more than 300 Orange Book patent listings across 20 different brand name products.